blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3737765

EP3737765 - ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  19.11.2021
Database last updated on 14.09.2024
FormerGrant of patent is intended
Status updated on  27.09.2021
FormerExamination is in progress
Status updated on  25.06.2021
FormerRequest for examination was made
Status updated on  16.10.2020
FormerThe international publication has been made
Status updated on  19.07.2019
Most recent event   Tooltip12.08.2024New entry: Legal effect of interlocutory decision 
Applicant(s)For all designated states
Curocell Inc.
11, Gukjegwahak 16-ro
Yuseong-gu
Daejeon, 34002 / KR
For all designated states
Korea Advanced Institute of Science and Technology
291 Daehak-ro
Guseong-dong, Yuseong-gu
Daejeon 34141 / KR
[2024/27]
Former [2020/47]For all designated states
Curocell Inc.
3rd floor, KHE Building
48 Yuseong-daero 1184 beon-gil
Yuseong-gu
Daejeon 34050 / KR
For all designated states
Korea Advanced Institute of Science and Technology
291 Daehak-ro
Guseong-dong, Yuseong-gu
Daejeon 34141 / KR
Inventor(s)01 / KIM, Chan Hyuk
291 Daehak-ro, Yuseong-gu
Daejeon 34141 / KR
02 / LEE, Young-Ho
Unit 2003, Building 208, 523 Doan Dong-ro,
Yuseong-gu
Daejeon 34189 / KR
03 / LEE, Yujean
Unit 602, Building 101, Noeun Hanwha Dream &
Green Apts. 33 Jijok Buk-ro, Yuseong-gu
Daejeon 34070 / KR
04 / LEE, HyeongJi
Unit 1216, Riviera i-Nuri 5, 445-4 Bongmyeong-
dong, Yuseong-gu
Daejeon 34168 / KR
05 / LEE, Sang Hoon
Unit 302, 210-83 Shinseong-dong, Yuseong-gu
Daejeon 34116 / KR
 [2020/47]
Representative(s)Reddie & Grose LLP
The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[N/P]
Former [2020/47]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Application number, filing date19738866.310.01.2019
[2020/47]
WO2019IB50194
Priority number, dateKR2018000423812.01.2018         Original published format: KR 20180004238
[2020/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019138354
Date:18.07.2019
Language:EN
[2019/29]
Type: A1 Application with search report 
No.:EP3737765
Date:18.11.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 18.07.2019 takes the place of the publication of the European patent application.
[2020/47]
Type: B1 Patent specification 
No.:EP3737765
Date:22.12.2021
Language:EN
[2021/51]
Search report(s)International search report - published on:KR18.07.2019
(Supplementary) European search report - dispatched on:EP14.04.2021
ClassificationIPC:C12N15/63, C07K14/725, C07K16/30, C12N5/0783, C12N15/113, A61K35/17, C12N15/10
[2021/19]
CPC:
C12N15/113 (EP,KR); C12N15/63 (KR); A61K2239/31 (EP,KR,US);
A61K2239/48 (EP,KR,US); A61K31/7088 (US); A61K38/177 (EP,US);
A61K38/1774 (US); A61K39/3955 (US); A61K39/4611 (EP,KR,US);
A61K39/4631 (EP,KR,US); A61K39/4636 (EP,KR,US); A61K39/464412 (EP,KR,US);
A61P35/00 (EP,US); C07K14/4702 (US); C07K14/7051 (EP,KR,US);
C07K14/70521 (US); C07K14/70578 (US); C07K16/2803 (EP,US);
C07K16/2809 (EP); C07K16/2818 (EP); C07K16/30 (KR);
C12N15/1075 (EP); C12N15/1138 (EP,US); C12N5/0636 (EP,KR,US);
C12N5/0637 (EP,KR,US); C12N5/0646 (EP,KR,US); A61K2039/505 (US);
C07K2317/31 (EP); C07K2317/53 (US); C07K2317/622 (EP,KR,US);
C07K2317/70 (EP); C07K2317/73 (EP); C07K2319/00 (EP);
C07K2319/02 (US); C07K2319/03 (EP,KR,US); C07K2319/30 (US);
C07K2319/33 (EP,US); C07K2319/715 (US); C12N2310/122 (US);
C12N2310/14 (EP,US); C12N2310/531 (US); C12N2320/31 (EP,US);
C12N2320/32 (US); C12N2330/51 (EP); C12N2510/00 (KR,US);
C12Q2525/301 (KR) (-)
C-Set:
C12N15/1075, C12Q2525/207 (EP);
C12N2310/531, C12N2310/14 (EP)
Former IPC [2020/47]C12N15/63, C07K14/725, C07K16/30, C12N5/0783, C12N15/113, A61K35/17
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/47]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERBESSERTE IMMUNZELLEN UNTER VERWENDUNG VON DUALER SHRNA UND ZUSAMMENSETZUNG DAMIT[2020/47]
English:ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME[2020/47]
French:CELLULES IMMUNES AMPLIFIÉES UTILISANT UN RNASH DOUBLE, ET COMPOSITIONS LES COMPRENANT[2020/47]
Entry into regional phase10.08.2020National basic fee paid 
10.08.2020Search fee paid 
10.08.2020Designation fee(s) paid 
10.08.2020Examination fee paid 
Examination procedure10.08.2020Examination requested  [2020/47]
08.09.2020Amendment by applicant (claims and/or description)
24.06.2021Despatch of a communication from the examining division (Time limit: M04)
31.08.2021Reply to a communication from the examining division
28.09.2021Communication of intention to grant the patent
11.11.2021Fee for grant paid
11.11.2021Fee for publishing/printing paid
11.11.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21207719.2  / EP4006153
Opposition(s)Opponent(s)01  21.09.2022  22.09.2022  ADMISSIBLE
ELKINGTON AND FIFE LLP
Prospect House
8 Pembroke Road
Sevenoaks
Kent TN13 1XR / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 [N/P]
Former [2022/43]
Opponent(s)01  21.09.2022  22.09.2022  ADMISSIBLE
ELKINGTON AND FIFE LLP
Prospect House 8 Pembroke Road Sevenoaks
Kent TN13 1XR / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
05.10.2022Invitation to proprietor to file observations on the notice of opposition
15.02.2023Reply of patent proprietor to notice(s) of opposition
28.02.2024Date of oral proceedings
04.04.2024Despatch of interlocutory decision in opposition
04.04.2024Despatch of minutes of oral proceedings
31.07.2024Legal effect of interlocutory decision in opposition
Appeal following opposition04.06.2024Appeal received No.  T0820/24
04.06.2024Payment of appeal fee
31.07.2024Result of appeal procedure: appeal of the proprietor withdrawn
Fees paidRenewal fee
13.01.2021Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU10.01.2019
AL22.12.2021
AT22.12.2021
CY22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
MK22.12.2021
RO22.12.2021
RS22.12.2021
SI22.12.2021
SK22.12.2021
SM22.12.2021
IE10.01.2022
BG22.03.2022
GR23.03.2022
IS22.04.2022
[2024/25]
Former [2024/23]AL22.12.2021
AT22.12.2021
CY22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
MK22.12.2021
RO22.12.2021
RS22.12.2021
SI22.12.2021
SK22.12.2021
SM22.12.2021
IE10.01.2022
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2024/20]AL22.12.2021
AT22.12.2021
CY22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SI22.12.2021
SK22.12.2021
SM22.12.2021
IE10.01.2022
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2023/10]AL22.12.2021
AT22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SI22.12.2021
SK22.12.2021
SM22.12.2021
IE10.01.2022
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2023/09]AL22.12.2021
AT22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SK22.12.2021
SM22.12.2021
IE10.01.2022
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2022/49]AL22.12.2021
AT22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SK22.12.2021
SM22.12.2021
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2022/42]AT22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SK22.12.2021
SM22.12.2021
BG22.03.2022
GR23.03.2022
IS22.04.2022
Former [2022/36]AT22.12.2021
CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SK22.12.2021
SM22.12.2021
BG22.03.2022
GR23.03.2022
Former [2022/35]CZ22.12.2021
EE22.12.2021
HR22.12.2021
LT22.12.2021
LV22.12.2021
RO22.12.2021
RS22.12.2021
SK22.12.2021
SM22.12.2021
BG22.03.2022
GR23.03.2022
Former [2022/33]HR22.12.2021
LT22.12.2021
LV22.12.2021
RS22.12.2021
SM22.12.2021
BG22.03.2022
GR23.03.2022
Former [2022/24]HR22.12.2021
LT22.12.2021
LV22.12.2021
RS22.12.2021
BG22.03.2022
GR23.03.2022
Former [2022/22]LT22.12.2021
RS22.12.2021
BG22.03.2022
Former [2022/21]RS22.12.2021
BG22.03.2022
Former [2022/19]BG22.03.2022
Documents cited:Search[A]WO2016126608  (NOVARTIS AG [CH], et al);
 [A]WO2017040945  (MEMORIAL SLOAN KETTERING CANCER CENTER [US]);
International search[A]US2014219975  (JUNE CARL H [US], et al);
 [A]US2014227237  (JUNE CARL H [US], et al);
 [X]WO2015142675  (NOVARTIS AG [CH], et al);
 [X]US2016311917  (BEATTY GREGORY [US], et al);
 [PX]WO2018012895  (CUROCELL INC [KR])
by applicantUS4690915
 US5858358
 US5883223
 US6352694
 US6534055
 US6692964
 US6797514
 US6867041
 US6887466
 US6905680
 US6905681
 US6905874
 US2006121005
 US7067318
 US7144575
 US7172869
 US7175843
 US7232566
 WO2016069282
OppositionUS2008293142
 WO2015142675
 WO2016126608
 US2016311917
 WO2017040945
 WO2018049471
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.